# AVASTIN® (bevacizumab) - Complete FDA Prescribing Information

**Source**: FDA DailyMed Database  
**Document ID**: 939b5d1f-9fb2-4499-80ef-0607aa6b114e  
**Initial U.S. Approval**: 2004  
**Last Updated**: September 2022  
**Extracted**: September 2024

---

## HIGHLIGHTS OF PRESCRIBING INFORMATION

*These highlights do not include all the information needed to use AVASTIN safely and effectively. See full prescribing information for AVASTIN.*

### INDICATIONS AND USAGE
Avastin is a vascular endothelial growth factor inhibitor indicated for:
- **Recurrent glioblastoma** in adults. (1.3)
- Multiple other cancer indications (see full prescribing information)

### DOSAGE AND ADMINISTRATION
- **Recurrent glioblastoma**: 10 mg/kg every 2 weeks (2.4)
- Withhold for at least 28 days prior to elective surgery (2.1)
- Do not administer for 28 days following major surgery until adequate wound healing (2.1)

### DOSAGE FORMS AND STRENGTHS
- Injection: 100 mg/4 mL (25 mg/mL) or 400 mg/16 mL (25 mg/mL) in single-dose vials (3)

### CONTRAINDICATIONS
None (4)

### WARNINGS AND PRECAUTIONS
- **Gastrointestinal Perforations and Fistula**: Discontinue for GI perforations, tracheoesophageal fistula, grade 4 fistula (5.1)
- **Surgery and Wound Healing Complications**: Withhold until adequate wound healing. Discontinue for necrotizing fasciitis (5.2)
- **Hemorrhage**: Severe or fatal hemorrhages. Discontinue for Grade 3-4 hemorrhage (5.3)
- **Arterial Thromboembolic Events (ATE)**: Discontinue for severe ATE (5.4)
- **Hypertension**: Monitor blood pressure and treat. Discontinue for hypertensive crisis (5.6)
- **Posterior Reversible Encephalopathy Syndrome (PRES)**: Discontinue (5.7)
- **Renal Injury and Proteinuria**: Monitor urine protein. Discontinue for nephrotic syndrome (5.8)
- **Embryo-Fetal Toxicity**: May cause fetal harm. Advise effective contraception (5.10)

### ADVERSE REACTIONS
Most common adverse reactions (>10%): epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis. (6.1)

---

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

#### 1.3 Recurrent Glioblastoma
**Avastin is indicated for the treatment of recurrent glioblastoma (GBM) in adults.**

### 2 DOSAGE AND ADMINISTRATION

#### 2.1 Important Administration Information
- Withhold for at least 28 days prior to elective surgery
- Do not administer until at least 28 days following major surgery and until adequate wound healing

#### 2.4 Recurrent Glioblastoma
**The recommended dosage is 10 mg/kg intravenously every 2 weeks.**

#### 2.9 Dosage Modifications for Adverse Reactions
**No dose reductions for Avastin are recommended.**

**Key Dosage Modifications:**
- **Gastrointestinal perforation**: Discontinue Avastin
- **Tracheoesophageal fistula**: Discontinue Avastin  
- **Grade 4 fistula**: Discontinue Avastin
- **Wound healing complications**: Withhold until adequate healing
- **Necrotizing fasciitis**: Discontinue Avastin
- **Grade 3-4 hemorrhage**: Discontinue Avastin
- **Severe arterial thromboembolism**: Discontinue Avastin
- **Grade 4 venous thromboembolism**: Discontinue Avastin
- **Hypertensive crisis/encephalopathy**: Discontinue Avastin
- **PRES**: Discontinue Avastin
- **Nephrotic syndrome**: Discontinue Avastin
- **Congestive heart failure**: Discontinue Avastin

#### 2.10 Preparation and Administration

**Preparation:**
- Use appropriate aseptic technique
- Withdraw necessary amount and dilute in 100 mL of 0.9% Sodium Chloride
- **DO NOT MIX WITH DEXTROSE SOLUTION**
- Discard unused portion (no preservatives)

**Administration:**
- **First infusion**: 90 minutes
- **Second infusion**: 60 minutes (if first tolerated)
- **Subsequent infusions**: 30 minutes (if second tolerated)

### 3 DOSAGE FORMS AND STRENGTHS
**Injection:** 100 mg/4 mL (25 mg/mL) or 400 mg/16 mL (25 mg/mL) clear to slightly opalescent, colorless to pale brown solution in single-dose vials.

### 4 CONTRAINDICATIONS
**None.**

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Gastrointestinal Perforations and Fistulae
- Serious, sometimes fatal GI perforation: 0.3% to 3% incidence
- Highest incidence in patients with prior pelvic radiation
- Majority occur within 50 days of first dose
- **Discontinue** for GI perforation, tracheoesophageal fistula, Grade 4 fistula, or fistula involving internal organs

#### 5.2 Surgery and Wound Healing Complications
- Wound healing complications: 15% (with Avastin) vs 4% (without)
- In GBM patients: 5% (with Avastin) vs 0.7% (without)
- **Withhold** for at least 28 days before elective surgery
- **Do not administer** for at least 28 days after major surgery
- **Discontinue** for necrotizing fasciitis

#### 5.3 Hemorrhage
- Two patterns: minor (Grade 1 epistaxis) and serious/fatal hemorrhage
- Up to 5-fold higher incidence with Avastin
- Grades 3-5 hemorrhage: 0.4% to 7% across studies
- **Do not administer** for recent hemoptysis ≥1/2 teaspoon
- **Discontinue** for Grade 3-4 hemorrhage

#### 5.4 Arterial Thromboembolic Events
- Serious, sometimes fatal ATE including stroke, MI, angina
- Grade 3-5 ATE: 5% (Avastin) vs ≤2% (chemotherapy alone)
- **Highest incidence in GBM patients**
- Risk factors: history of ATE, diabetes, age >65
- **Discontinue** for severe ATE

#### 5.5 Venous Thromboembolic Events
- Increased VTE risk observed across studies
- **Discontinue** for Grade 4 VTE including pulmonary embolism

#### 5.6 Hypertension
- Grade 3-4 hypertension: 5% to 18% incidence
- Monitor BP every 2-3 weeks during treatment
- **Withhold** for severe hypertension not controlled medically
- **Discontinue** for hypertensive crisis or encephalopathy

#### 5.7 Posterior Reversible Encephalopathy Syndrome
- PRES reported in <0.5% of patients
- Onset: 16 hours to 1 year after first dose
- Symptoms: headache, seizure, confusion, visual disturbances
- **Discontinue** for PRES (MRI confirmation needed)

#### 5.8 Renal Injury and Proteinuria
- Higher incidence and severity with Avastin
- Grade 3-4 proteinuria: 0.7% to 7%
- Median onset: 5.6 months
- Did not resolve in 40% of patients
- **Monitor** with dipstick urinalysis
- **Withhold** for proteinuria ≥2 grams/24 hours
- **Discontinue** for nephrotic syndrome

#### 5.9 Infusion-Related Reactions
- IRRs include hypertension, wheezing, hypersensitivity
- First dose reactions: <3% of patients
- Severe reactions: 0.4% of patients
- **Decrease rate** for mild reactions
- **Interrupt infusion** for clinically significant reactions
- **Discontinue** for severe reactions

#### 5.10 Embryo-Fetal Toxicity
- May cause fetal harm based on mechanism and animal studies
- Congenital malformations in rabbits at clinical doses
- **Advise** pregnant women of potential fetal risk
- **Advise** effective contraception during treatment and 6 months after

### 6 ADVERSE REACTIONS

#### 6.1 Clinical Trials Experience

**Recurrent Glioblastoma - Most Common Adverse Reactions:**
- Epistaxis
- Headache  
- Hypertension
- Proteinuria
- Hemorrhage

**Serious Adverse Reactions:**
- 22% of patients discontinued due to adverse reactions
- Arterial thromboembolic events (higher in GBM patients)
- CNS hemorrhage: 2.5% Grade ≥3

### 8 USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy
- **May cause fetal harm**
- Advise females to use effective contraception during treatment and 6 months after last dose

#### 8.2 Lactation
- **Advise not to breastfeed** during treatment and 6 months after last dose

#### 8.3 Females and Males of Reproductive Potential
- **Contraception**: Effective contraception required
- **Infertility**: May impair fertility

#### 8.4 Pediatric Use
Safety and effectiveness not established

#### 8.5 Geriatric Use
No overall differences in safety observed, but monitor closely

### 11 DESCRIPTION
Bevacizumab is a humanized monoclonal antibody that binds and inhibits vascular endothelial growth factor A (VEGF-A).

### 12 CLINICAL PHARMACOLOGY

#### 12.1 Mechanism of Action
Binds and inhibits VEGF-A, preventing interaction with VEGF receptors on endothelial cells.

#### 12.3 Pharmacokinetics
- **Half-life**: Approximately 20 days (range 11-50 days)
- **Clearance**: 0.207-0.262 mL/day/kg
- **Volume of distribution**: 2.73-3.25 L

### 14 CLINICAL STUDIES

#### 14.4 Recurrent Glioblastoma
**Study AVF3708g**: Single-arm study in 85 patients with recurrent GBM
- **Objective response rate**: 25.9% (95% CI: 17.0%-36.1%)
- **Complete response**: 2 patients (2.4%)
- **Partial response**: 20 patients (23.5%)
- **Median PFS**: 4.2 months
- **6-month PFS rate**: 29%

### 16 HOW SUPPLIED/STORAGE AND HANDLING
- Store at 36°F to 46°F (2°C to 8°C)
- Protect from light
- Do not freeze or shake
- Single-use vial: discard unused portion

---

*This document contains the complete FDA prescribing information for AVASTIN® (bevacizumab) for recurrent glioblastoma extracted from DailyMed database. Always refer to current FDA labeling for the most up-to-date information.*